Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PENICILLAMINE vs ACTIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Chelates heavy metals (copper, mercury, lead, arsenic) forming soluble complexes excreted renally; also reduces cystine formation in cystinuria by disulfide exchange; immunosuppressive effects via inhibition of T-cell function and collagen synthesis.
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Wilson's disease,Cystinuria,Rheumatoid arthritis,Lead poisoning,Mercury poisoning,Arsenic poisoning
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
250-500 mg orally 4 times daily, with a maximum of 2 g/day; for rheumatoid arthritis, initial dose 125-250 mg/day, increase by 125-250 mg every 1-3 months to usual maintenance of 500-750 mg/day in divided doses.
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
Terminal half-life: 1.5–2 hours for penicillamine; after chronic dosing, a slower phase (t1/2 ~40 hours) appears due to tissue binding. Clinical context: Dosing interval typically 6–8 hours; accumulation may occur in renal impairment.
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Hepatic metabolism to S-methyl-penicillamine and penicillamine disulfide; also undergoes renal excretion.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Renal: ~80% as unchanged drug and metabolites; fecal: ~20% (via biliary elimination).
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
~80% bound to plasma proteins, primarily albumin.
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
Vd: 0.1–0.2 L/kg; indicates distribution mainly in extracellular fluid and limited tissue penetration, though accumulates in skin and connective tissue.
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Oral: 40–70% (variable due to food and metal ions).
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
Cr Cl >=50 m L/min: no adjustment; Cr Cl 30-49 m L/min: reduce dose by 50%; Cr Cl 10-29 m L/min: reduce dose by 75%; Cr Cl <10 m L/min: avoid use.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
No specific adjustments recommended; use with caution in severe hepatic impairment.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
For Wilson disease: 250 mg/m²/day orally in divided doses; for cystinuria: 30 mg/kg/day in divided doses; for rheumatoid arthritis: 2.5-5 mg/kg/day, titrated slowly.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
Initiate at low end of dosing range; monitor renal function closely; increased risk of hematologic and autoimmune adverse effects.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
None explicitly issued by FDA.
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
Bone marrow suppression (leukopenia, thrombocytopenia, aplastic anemia), proteinuria/nephrotic syndrome, autoimmune reactions (myasthenia gravis, Goodpasture's syndrome, lupus-like syndrome), severe skin reactions (toxic epidermal necrolysis), hepatotoxicity, cross-allergenicity with penicillin. Requires monitoring of CBC, urinalysis, liver function.
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
History of aplastic anemia or agranulocytosis, severe renal insufficiency, pregnancy (especially first trimester), breastfeeding, hypersensitivity to penicillamine or penicillin.
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
Avoid high-protein meals and dairy products around dosing; they decrease penicillamine absorption. Separate intake from iron supplements, antacids, and zinc by at least 2 hours. For cystinuria, maintain high fluid intake and possibly restrict sodium and methionine-rich foods (e.g., meats, dairy) as part of therapy.
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
First trimester: Known teratogen; associated with cutis laxa, congenital hip dislocation, and other skeletal abnormalities. Contraindicated unless treatment for Wilson disease or cystinuria. Second/third trimesters: Risk of fetal connective tissue defects; avoid unless essential.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
Excreted in breast milk; M/P ratio approximately 0.1. Low concentrations are present; however, due to potential adverse effects (e.g., rash, bone marrow suppression), caution is advised. Consider monitoring infant for rash or blood dyscrasias.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
No specific dose adjustment is recommended based on pharmacokinetic changes alone; however, due to potential teratogenicity, use only when necessary. Therapeutic drug monitoring may be considered to ensure efficacy without excessive toxicity.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
Penicillamine is a chelating agent used for Wilson disease, cystinuria, and rheumatoid arthritis. Monitor for bone marrow suppression, proteinuria, and autoimmune reactions. Administer on an empty stomach (1 hour before or 2 hours after meals). Avoid concurrent use with gold, antimalarials, or immunosuppressants due to increased toxicity. Discontinue if rash, fever, or lymphadenopathy develop.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
Take penicillamine on an empty stomach, at least 1 hour before or 2 hours after meals.,Avoid taking with milk, antacids, or iron supplements as they reduce absorption.,Report any unexplained bruising, bleeding, sore throat, or fever immediately.,Watch for signs of proteinuria (foamy urine) or hematuria (blood in urine).,Do not stop abruptly; dose tapering is required.,Use effective contraception; penicillamine can cause fetal harm.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
"Almasilate, an aluminum-containing antacid, can adsorb penicillamine in the gastrointestinal tract, forming an insoluble complex that reduces penicillamine absorption. This leads to decreased serum concentrations of penicillamine, potentially diminishing its therapeutic effect in diseases such as rheumatoid arthritis or Wilson's disease. Clinically, this interaction may result in loss of disease control or require dose adjustments."
"Calcium carbonate, a common antacid and calcium supplement, chelates with penicillamine in the gastrointestinal tract, forming an insoluble complex that reduces penicillamine absorption. This interaction significantly decreases the bioavailability and serum concentration of penicillamine, potentially compromising its therapeutic efficacy in treating conditions such as rheumatoid arthritis or Wilson's disease. Clinical outcomes may include loss of disease control or increased disease activity, particularly if the drugs are taken concomitantly."
"Concomitant administration of penicillamine and teriflunomide may significantly increase the serum concentration of teriflunomide, primarily due to penicillamine's inhibition of the organic anion transporter 3 (OAT3)-mediated renal elimination of teriflunomide. Elevated teriflunomide levels heighten the risk of dose-dependent adverse effects, including hepatotoxicity, peripheral neuropathy, and immunosuppression. This interaction warrants careful monitoring and potential dose adjustment to avoid toxicity."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PENICILLAMINE vs ACTIQ, answered by our medical review team.
PENICILLAMINE is a Chelating Agent that works by Chelates heavy metals (copper, mercury, lead, arsenic) forming soluble complexes excreted renally; also reduces cystine formation in cystinuria by disulfide exchange; immunosuppressive effects via inhibition of T-cell function and collagen synthesis.. ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PENICILLAMINE and ACTIQ depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PENICILLAMINE is: 250-500 mg orally 4 times daily, with a maximum of 2 g/day; for rheumatoid arthritis, initial dose 125-250 mg/day, increase by 125-250 mg every 1-3 months to usual maintenance of 500-750 mg/day in divided doses.. The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PENICILLAMINE and ACTIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PENICILLAMINE is classified as Category C. First trimester: Known teratogen; associated with cutis laxa, congenital hip dislocation, and other skeletal abnormalities. Contraindicated unless treatment for Wilson disease or c. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.